This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Interventions
Lanthanum carbonate was compared against calcium-based binders, as second-line treatment after a calcium-based binder.
Location/setting
UK/secondary care.
Methods

Analytical approach:
The analysis was based on a standard decision tree, followed by a Markov model, with a lifetime horizon. The authors stated that it was carried out from the perspective of the UK NHS.
Effectiveness data:
The clinical inputs were from a selection of published studies, with some assumptions by two UK clinical experts. The main inputs related to drug efficacy and were from two randomised trials; one of 57 patients who had not started dialysis and were treated with lanthanum carbonate and the other of patients on dialysis who were treated with lanthanum carbonate (n=123) or calcium-based binders (n=257). Other data were from published epidemiological studies. The baseline expected survival was from long-term observational data. The adverse effects of the drugs (mainly vomiting) were from the two clinical trials.
Monetary benefit and utility valuations:
The utility values were from a recent systematic review of health conditions in patients on or before dialysis. The utility decrements for vomiting were from a published study.
Measure of benefit:
Life-years and quality-adjusted life-years (QALYs) were the summary benefit measures. A 3.5% annual discount rate was applied.
Cost data:
The economic analysis included the costs of the drugs and dialysis. Most of the resource consumption estimates were from the two clinical trials. The drug costs were from the British National Formulary and the dialysis costs were a weighted average of the UK estimates for haemodialysis and peritoneal dialysis. The costs of dialysis in added lifeyears were not included in the base case. All costs were in UK pounds sterling (£) and were discounted at an annual rate of 3.5%. The price year was 2009.
Analysis of uncertainty:
A probabilistic sensitivity analysis was carried out to assess the uncertainty, using recommended probability distributions for each type of input. Credible intervals around the model outcomes were calculated. The dialysis costs in added life-years were included in a scenario analysis and other scenarios were analysed.
Results
In patients who had not started dialysis, lanthanum carbonate led to a gain of 69.4 life-years or 44.1 QALYs, and saved £339 over a calcium-based binder. Lanthanum carbonate was dominant, as it was more effective and less expensive. At a willingness-to-pay threshold of £30,000 per QALY, the net monetary benefit was £1,700, suggesting that lanthanum carbonate was highly cost-effective.
In patients on dialysis, lanthanum carbonate led to a gain of 91.9 life-years or 55.8 QALYs, at an additional cost of £386. The incremental cost per life-year gained with lanthanum carbonate over a calcium-based binder was £4,200 and the incremental cost per QALY gained was £6,900. The net monetary benefit was £1,300.
The base-case results were stable in most scenarios, but when future dialysis costs were included, the incremental cost per QALY gained rose to £48,600 for patients before dialysis and £63,000 for patients on dialysis. When the mortality on dialysis was varied, the incremental cost per QALY gained rose to £22,300 for patients on dialysis.
